XERIS BIOPHARMA HOLDINGS, INC. Long-Term Debt, Maturity, after Year Five
XERIS BIOPHARMA HOLDINGS, INC. (XERS) had Long-Term Debt, Maturity, after Year Five of $0 as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2026-08-06
- 2026-06-30: Long-Term Debt, Maturity, after Year Five $0.00.
- 2026-03-31: Long-Term Debt, Maturity, after Year Five $0.00.
- 2025-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
- 2024-12-31: Long-Term Debt, Maturity, after Year Five $0.00.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-06 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |